$AADI
Aadi Bioscience, Inc.

2022 Q3 Form 10-Q Financial Statement

#000162828022022208 Filed on August 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $4.245M $3.437M $2.307M
YoY Change 1822.5%
Cost Of Revenue $593.0K $341.0K $179.0K
YoY Change
Gross Profit $3.652M $3.096M $2.128M
YoY Change
Gross Profit Margin 86.03% 90.08% 92.24%
Selling, General & Admin $9.915M $10.01M $9.148M
YoY Change 33.97% 1105.54% 1524.87%
% of Gross Profit 271.5% 323.19% 429.89%
Research & Development $8.773M $7.726M $6.794M
YoY Change 52.47% 153.73% 86.44%
% of Gross Profit 240.22% 249.55% 319.27%
Depreciation & Amortization $12.00K $27.00K $74.00K
YoY Change 163.74% 131.36% 3600.0%
% of Gross Profit 0.33% 0.87% 3.48%
Operating Expenses $18.69M $17.73M $15.94M
YoY Change -78.6% 357.6% 184.53%
Operating Profit -$15.04M -$18.36M -$13.81M
YoY Change -82.78% 373.81% 238.0%
Interest Expense $58.00K $58.00K $58.00K
YoY Change -63.06% -74.45% -74.11%
% of Operating Profit
Other Income/Expense, Net $562.0K $100.0K -$43.00K
YoY Change 152.02% -95.73% -103.7%
Pretax Income -$14.47M -$18.26M -$13.86M
YoY Change -83.38% 1090.35% 153.05%
Income Tax $0.00 $9.000K $0.00
% Of Pretax Income
Net Earnings -$14.50M -$18.30M -$13.86M
YoY Change -83.35% 1091.41% 153.05%
Net Earnings / Revenue -341.58% -532.44% -600.65%
Basic Earnings Per Share -$0.68 -$0.87 -$0.66
Diluted Earnings Per Share -$0.68 -$0.87 -$662.5K
COMMON SHARES
Basic Shares Outstanding 21.02M shares 20.97M shares 20.91M shares
Diluted Shares Outstanding 21.27M shares 20.97M shares 20.91M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $183.0M $118.7M $129.8M
YoY Change 13.4% 222.51% 232.87%
Cash & Equivalents $134.8M $118.7M $129.8M
Short-Term Investments $48.19M
Other Short-Term Assets $3.861M $2.808M $2.861M
YoY Change 500.47% 385.43% 43.72%
Inventory $734.0K $727.0K $202.0K
Prepaid Expenses
Receivables $2.261M $2.063M $2.708M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $189.9M $124.3M $135.6M
YoY Change 17.19% 232.49% 230.79%
LONG-TERM ASSETS
Property, Plant & Equipment $457.0K $357.0K $619.0K
YoY Change 3164.29% 3677.78% 335.58%
Goodwill
YoY Change
Intangibles $0.00 $0.00
YoY Change -100.0%
Long-Term Investments
YoY Change
Other Assets $2.210M $2.291M $2.337M
YoY Change -2.34% 11355.0% 11585.0%
Total Long-Term Assets $4.240M $4.301M $6.699M
YoY Change -37.22% 14503.42% 4032.38%
TOTAL ASSETS
Total Short-Term Assets $189.9M $124.3M $135.6M
Total Long-Term Assets $4.240M $4.301M $6.699M
Total Assets $194.1M $128.6M $142.3M
YoY Change 15.01% 243.73% 245.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.920M $3.619M $4.010M
YoY Change -24.69% 384.55% 774.29%
Accrued Expenses $13.60M $8.653M $7.337M
YoY Change 117.55% 492.18% 339.2%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.89M $12.60M $11.51M
YoY Change 54.67% 470.45% 440.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $7.104M $109.0K $6.181M
YoY Change 1258.32%
Total Long-Term Liabilities $7.104M $109.0K $6.181M
YoY Change 13.12%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.89M $12.60M $11.51M
Total Long-Term Liabilities $7.104M $109.0K $6.181M
Total Liabilities $25.00M $19.91M $17.69M
YoY Change 40.05% 801.5% 730.88%
SHAREHOLDERS EQUITY
Retained Earnings -$189.3M -$174.8M -$156.5M
YoY Change 49.41%
Common Stock $358.5M $283.5M $281.2M
YoY Change 29.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $169.1M $108.7M $124.6M
YoY Change
Total Liabilities & Shareholders Equity $194.1M $128.6M $142.3M
YoY Change 15.01% 243.73% 245.76%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$14.50M -$18.30M -$13.86M
YoY Change -83.35% 1091.41% 153.05%
Depreciation, Depletion And Amortization $12.00K $27.00K $74.00K
YoY Change 163.74% 131.36% 3600.0%
Cash From Operating Activities -$8.195M -$10.72M -$19.42M
YoY Change 99.81% 381.39% -283.8%
INVESTING ACTIVITIES
Capital Expenditures -$102.0K -$241.0K $23.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$48.14M
YoY Change -291.04%
Cash From Investing Activities -$48.24M -$241.0K -$23.00K
YoY Change -291.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 72.52M -87.00K 298.0K
YoY Change -48.79% -352.25% 324.02%
NET CHANGE
Cash From Operating Activities -8.195M -10.72M -19.42M
Cash From Investing Activities -48.24M -241.0K -23.00K
Cash From Financing Activities 72.52M -87.00K 298.0K
Net Change In Cash 16.08M -11.05M -19.14M
YoY Change -90.12% 403.92% -281.2%
FREE CASH FLOW
Cash From Operating Activities -$8.195M -$10.72M -$19.42M
Capital Expenditures -$102.0K -$241.0K $23.00K
Free Cash Flow -$8.093M -$10.48M -$19.44M
YoY Change 370.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001422142
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38560
dei Entity Registrant Name
EntityRegistrantName
AADI BIOSCIENCE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
61-1547850
dei Entity Address Address Line1
EntityAddressAddressLine1
17383 Sunset Boulevard
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite A250
dei Entity Address City Or Town
EntityAddressCityOrTown
Pacific Palisades
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90272
dei City Area Code
CityAreaCode
424
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
dei Local Phone Number
LocalPhoneNumber
744-8055
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21016833 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
118737000 usd
dei Security12b Title
Security12bTitle
Common stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
AADI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
148989000 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2063000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
727000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
0 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2808000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2283000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
124335000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
151272000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
357000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
57000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1653000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
557000 usd
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3811000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2291000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2213000 usd
CY2022Q2 us-gaap Assets
Assets
128636000 usd
CY2021Q4 us-gaap Assets
Assets
157910000 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3619000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6439000 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8653000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8703000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
324000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
131000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12596000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15273000 usd
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
109000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1444000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
474000 usd
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 aadi Due To Licensor
DueToLicensor
5757000 usd
CY2021Q4 aadi Due To Licensor
DueToLicensor
5757000 usd
CY2022Q2 us-gaap Liabilities
Liabilities
19906000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
21504000 usd
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20894695 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
341000 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21016833 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21016833 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20894695 shares
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
283539000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
279089000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-174811000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-142685000 usd
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
108730000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
136406000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128636000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
157910000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3437000 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5744000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
120000 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10006000 usd
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
830000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
19154000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1393000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7726000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3045000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14519000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6689000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
520000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18360000 usd
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
3875000 usd
us-gaap Costs And Expenses
CostsAndExpenses
37917000 usd
us-gaap Costs And Expenses
CostsAndExpenses
8082000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 usd
CY2022Q2 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
3724000 usd
CY2021Q2 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 usd
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
3724000 usd
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
21797000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3875000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-32173000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-7962000 usd
CY2022Q2 aadi Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
0 usd
CY2021Q2 aadi Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
-2371000 usd
aadi Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
0 usd
aadi Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
-1206000 usd
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2021Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
196000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
196000 usd
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
158000 usd
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
171000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
58000 usd
CY2021Q2 us-gaap Interest Expense
InterestExpense
227000 usd
us-gaap Interest Expense
InterestExpense
115000 usd
us-gaap Interest Expense
InterestExpense
451000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
100000 usd
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2341000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
56000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
952000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18260000 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1534000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-32117000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7010000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9000 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-18269000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1536000 usd
us-gaap Net Income Loss
NetIncomeLoss
-32126000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7012000 usd
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.76
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.76
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20970459 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20970459 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2542358 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2542358 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20942804 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20942804 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2542358 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2542358 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
136406000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1781000 usd
CY2022Q1 aadi Stock Issued During Period Value Warrant Exercised
StockIssuedDuringPeriodValueWarrantExercised
54000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
244000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-13857000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
124628000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2235000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
136000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-18269000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
108730000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-12432000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
36000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5476000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-17872000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
39000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1536000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-19369000 usd
us-gaap Net Income Loss
NetIncomeLoss
-32126000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7012000 usd
aadi Impairment Of Acquired Contract Intangible Asset
ImpairmentOfAcquiredContractIntangibleAsset
3724000 usd
aadi Impairment Of Acquired Contract Intangible Asset
ImpairmentOfAcquiredContractIntangibleAsset
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4016000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
75000 usd
aadi Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
0 usd
aadi Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
-1206000 usd
aadi Non Cash Interest Expense
NonCashInterestExpense
115000 usd
aadi Non Cash Interest Expense
NonCashInterestExpense
451000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
196000 usd
aadi Operating Lease Expense Non Cash
OperatingLeaseExpenseNonCash
157000 usd
aadi Operating Lease Expense Non Cash
OperatingLeaseExpenseNonCash
89000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
101000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2063000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-14149000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
727000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
524000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
111000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-284000 usd
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2500000 shares
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-90000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-88000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3111000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1223000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
109000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30135000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
7378000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
264000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
us-gaap Other Payments To Acquire Businesses
OtherPaymentsToAcquireBusinesses
0 usd
us-gaap Other Payments To Acquire Businesses
OtherPaymentsToAcquireBusinesses
157000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-264000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-157000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
380000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
54000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
223000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
211000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-30188000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7220000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
148989000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4455000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
118801000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11675000 usd
us-gaap Interest Paid Net
InterestPaidNet
115000 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
9000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
75000 usd
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
151000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
51000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1210000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2021Q3 aadi Anniversary Period Of Closing Of Merger Agreement
AnniversaryPeriodOfClosingOfMergerAgreement
P20Y
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-174800000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-18300000 usd
us-gaap Net Income Loss
NetIncomeLoss
-32100000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
118800000 usd
CY2021Q3 us-gaap Shares Outstanding
SharesOutstanding
8100000 shares
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Use Of Estimates
UseOfEstimates
Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and accompanying notes. In the opinion of management, all adjustments that are considered necessary for fair presentation have been included. The most significant estimates in the Company’s condensed consolidated financial statements relate to fair value of the intangible asset, fair value of the convertible promissory notes, gross-to-net accruals, stock-based compensation expense and accrued research and development costs. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents and certain investments in money market funds. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since inception.</span></div>
us-gaap Debt Instrument Term
DebtInstrumentTerm
P1Y
CY2022Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
13000 usd
CY2021Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
0 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
118737000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
148989000 usd
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
64000 usd
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
0 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
118801000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
148989000 usd
CY2022Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
0 usd
CY2022Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
144000 usd
CY2022Q2 us-gaap Allowance For Doubtful Accounts Premiums And Other Receivables
AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
100000 usd
CY2021Q4 us-gaap Allowance For Doubtful Accounts Premiums And Other Receivables
AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
0 usd
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
0 usd
CY2022Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
570000 usd
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
0 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
727000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
0 usd
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P14Y3M18D
CY2021Q2 us-gaap Finite Lived Intangible Assets Fair Value Disclosure
FiniteLivedIntangibleAssetsFairValueDisclosure
0 usd
CY2022Q2 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
3700000 usd
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
3700000 usd
CY2020Q1 aadi Convertible Notes Interest Rate For Remaining Sixth Months Term Until Maturity At Twelve Months
ConvertibleNotesInterestRateForRemainingSixthMonthsTermUntilMaturityAtTwelveMonths
0.10
CY2021Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
74200000 usd
CY2021Q3 us-gaap Finite Lived Intangible Assets Fair Value Disclosure
FiniteLivedIntangibleAssetsFairValueDisclosure
3900000 usd
aadi Percentage Of Future Net Cash Proceeds Will Be Remitted To Contingent Value Rights Holders
PercentageOfFutureNetCashProceedsWillBeRemittedToContingentValueRightsHolders
0.90
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P14Y3M18D
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
19000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
87000 usd
CY2021Q4 aadi Accrued Clinical Current
AccruedClinicalCurrent
2507000 usd
CY2022Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1682000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3811000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
87000 usd
CY2022Q2 aadi Finite Lived Intangible Assets Impaired Accumulated Impairment Loss
FiniteLivedIntangibleAssetsImpairedAccumulatedImpairmentLoss
3724000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8653000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8703000 usd
CY2022Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2172000 usd
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1465000 usd
CY2022Q2 aadi Accrued Clinical Current
AccruedClinicalCurrent
1597000 usd
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
152000 usd
CY2022Q2 aadi Accrued Contract Manufacturing Current
AccruedContractManufacturingCurrent
1099000 usd
CY2021Q4 aadi Accrued Contract Manufacturing Current
AccruedContractManufacturingCurrent
2287000 usd
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
930000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1948000 usd
CY2022Q2 aadi Accrued Liabilities Other Sales Related Expenses Current
AccruedLiabilitiesOtherSalesRelatedExpensesCurrent
771000 usd
CY2021Q4 aadi Accrued Liabilities Other Sales Related Expenses Current
AccruedLiabilitiesOtherSalesRelatedExpensesCurrent
0 usd
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
402000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
344000 usd
CY2020Q1 aadi Proceeds From Issuance Of Convertible Notes
ProceedsFromIssuanceOfConvertibleNotes
1000000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1653000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
557000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
324000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
131000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1444000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
474000 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1768000 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
605000 usd
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
107000 usd
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
46000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
157000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
91000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
90000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
91000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
201000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
489000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
502000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
310000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
230000 usd
CY2022Q2 aadi Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
388000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2120000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
352000 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1768000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
324000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1444000 usd
CY2022Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P4Y11M26D
CY2022Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0744
CY2022Q2 aadi Royalties Were Accrued On Product Sales
RoyaltiesWereAccruedOnProductSales
200000 usd
aadi Royalties Were Accrued On Product Sales
RoyaltiesWereAccruedOnProductSales
400000 usd
aadi Right To Terminate License Agreement
RightToTerminateLicenseAgreement
P120D
aadi Upfront Payment For License Agreement
UpfrontPaymentForLicenseAgreement
14000000 usd
CY2021Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14000000 usd
CY2021Q1 aadi Upfront Payment For License Agreement
UpfrontPaymentForLicenseAgreement
14000000 usd
aadi Amount Of Certain Development Regulatory And Sales Milestones Payments Eligible To Receive Under License Agreement
AmountOfCertainDevelopmentRegulatoryAndSalesMilestonesPaymentsEligibleToReceiveUnderLicenseAgreement
257000000 usd
CY2019Q4 aadi Proceeds From Issuance Of Convertible Notes
ProceedsFromIssuanceOfConvertibleNotes
8100000 usd
CY2019Q4 aadi Convertible Notes Interest Rate For Fourth Month Date Of Loan Agreement
ConvertibleNotesInterestRateForFourthMonthDateOfLoanAgreement
0.06
CY2020Q1 aadi Convertible Notes Interest Rate For Fourth Month Date Of Loan Agreement
ConvertibleNotesInterestRateForFourthMonthDateOfLoanAgreement
0.06
CY2019Q4 aadi Convertible Notes Interest Rate For Fifth And Sixth Month Date Of Loan Agreement
ConvertibleNotesInterestRateForFifthAndSixthMonthDateOfLoanAgreement
0.08
CY2020Q1 aadi Convertible Notes Interest Rate For Fifth And Sixth Month Date Of Loan Agreement
ConvertibleNotesInterestRateForFifthAndSixthMonthDateOfLoanAgreement
0.08
CY2019Q4 aadi Convertible Notes Interest Rate For Remaining Sixth Months Term Until Maturity At Twelve Months
ConvertibleNotesInterestRateForRemainingSixthMonthsTermUntilMaturityAtTwelveMonths
0.10
us-gaap Debt Instrument Term
DebtInstrumentTerm
P1Y
CY2020Q4 us-gaap Debt Instrument Term
DebtInstrumentTerm
P2Y
CY2021Q2 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
4.80
CY2021Q3 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
698018 shares
CY2021Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
9500000 usd
CY2021 aadi Gains Losses On Conversion Of Convertible Notes
GainsLossesOnConversionOfConvertibleNotes
400000 usd
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21016833 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20894695 shares
CY2021Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2558218 shares
CY2021Q3 aadi Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
145400000 usd
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0 usd
CY2022Q2 aadi Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
1 vote
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2781000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
363851 shares
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
9000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1749876 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.71
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M23D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10007000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1209638 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
17.11
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
114638 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
107523 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
25.03
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2737353 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.84
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M4D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.22
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P5Y2M15D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2291000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
862938 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
57889 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1209638 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
57889 shares
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
2235000 usd
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
39000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4016000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
75000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.08
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.96
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q2 aadi Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Outstanding Extended Exercise Ability Number Of Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndOutstandingExtendedExerciseAbilityNumberOfShares
64436 shares
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
29166 shares
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
36666 shares
CY2019Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
40000 shares
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.29
CY2022Q2 aadi Number Of Class Of Warrants Exercised
NumberOfClassOfWarrantsExercised
0 shares
aadi Number Of Class Of Warrants Exercised
NumberOfClassOfWarrantsExercised
7500 shares
CY2022Q2 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
9000 usd
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2000 usd
CY2021Q2 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2000 usd
CY2022Q2 aadi Accrued Clinical And Contract Manufacturing Expense
AccruedClinicalAndContractManufacturingExpense
2700000 usd
CY2021Q4 aadi Accrued Clinical And Contract Manufacturing Expense
AccruedClinicalAndContractManufacturingExpense
4800000 usd

Files In Submission

Name View Source Status
0001628280-22-022208-index-headers.html Edgar Link pending
0001628280-22-022208-index.html Edgar Link pending
0001628280-22-022208.txt Edgar Link pending
0001628280-22-022208-xbrl.zip Edgar Link pending
aadi-20220630.htm Edgar Link pending
aadi-20220630.xsd Edgar Link pending
aadi-20220630xex311.htm Edgar Link pending
aadi-20220630xex312.htm Edgar Link pending
aadi-20220630xex321.htm Edgar Link pending
aadi-20220630xex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
aadi-20220630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
aadi-20220630_pre.xml Edgar Link unprocessable
aadi-20220630_lab.xml Edgar Link unprocessable
aadi-20220630_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
aadi-20220630_cal.xml Edgar Link unprocessable